We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Molecular Biological Assay Applied to Cancer Diagnostics

By LabMedica International staff writers
Posted on 21 Sep 2011
Minute particles that measure micro ribonucleic acid (miRNA) levels have been utilized in tissue samples to provide a method to scan and diagnose cancer. More...


The technology uses an array of particles that attach themselves to a specific type of miRNA and when exposed to tissue, blood samples or purified RNA, these particles enable a miRNA profile to be created.

Chemical engineers at Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) successfully used hydrogel particles, with a length of around 200 μm, to detect more easily and efficiently miRNA dysregulation patterns in samples taken from four individuals with cancer. Hydrogels are a type of polymer chain network that attract water causing the attachment of nucleic acids. The hydrogel particles are ornamented with millions of identical strands of DNA. The strands are complimentary to a specific miRNA target sequence. Consequently, miRNA in a blood sample will be attracted to and attach to the DNA on the hydrogel particle.

By mixing the hydrogel particles with a blood sample, any miRNA present binds to its respective DNA. The DNA strands on the hydrogel contain a short sequence that then binds to a fluorescent probe at the completion of the test. A custom designed microfluidic scanner is used to measure rapidly each particle's fluorescence, thus revealing how much miRNA is present. The scanner also reads a chemical barcode imprinted on each hydrogel particle, which identifies the type of miRNA being detected. The entire process is complete in less than three hours. By adding multiple DNA label sequences to each miRNA target, increases the sensitivity of the hydrogel miRNA-detection particles by as much as 100 times. This new approach is more accurate because different miRNA strands have different shapes, which affect how easily they bind to the DNA markers and using mixed DNA markers helps avoid this anomaly.

Patrick S. Doyle PhD, the lead author and a professor at MIT, and colleagues are now beginning work with medical researchers to study the use of miRNA detection for use in other diseases such as heart disease and HIV. Firefly Bioworks (Cambridge, MA, USA) will license the technology for the custom-made scanner that is needed to detect the fluorescence of the hydrogels, with an aim of providing a unit for commercial use. The study was published on August 3, 2011, in the journal Analytical Chemistry.

Related Links:
Massachusetts Institute of Technology
Firefly Bioworks



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.